Navigation Links
DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
Date:1/8/2008

Patent Protects Very Low Dose Glucagon ahead of Phase 2 Clinical Trials in

2008

SAN FRANCISCO, Jan. 8 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company developing treatments for metabolic diseases, announced today that it has secured a critical patent from the U.S. Patent and Trademark Office for the use of very low dose glucagon, or DIO-901, in the prevention of insulin-induced hypoglycemia in diabetes patients. The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon.

"This patent protection strengthens our commitment to delivering the first product to the market for the prevention of insulin-induced hypoglycemia in diabetes," CEO David Cory said. "DIO-901 is the only therapeutic in development to prevent insulin-induced hypoglycemia, which is known to limit optimal glycemic control and cause recurring medical complications in most people with type 1 diabetes, in many with type 2 diabetes, and is sometimes fatal."

Insulin-induced hypoglycemia is the limiting factor in the glycemic management of diabetes. Were it not for the barrier of hypoglycemia, people with diabetes might achieve normal HbA1c levels over a lifetime of diabetes. Reduction of mean glycemia over time prevents or delays microvascular complications -- retinopathy, nephropathy, and neuropathy -- in both type 1 and type 2 diabetes. DIO-901 is expected to begin Phase 2 clinical testing later this year and has received Fast Track status from the Food and Drug Administration, underscoring the great unmet medical need in the prevention of insulin-induced hypoglycemia.

DiObex's latest patent, U.S. Patent No. 7,314,859, builds on a growing patent portfolio protecting its product candidates for metabolic diseases. In addition to the recently issued U.S. patent, DiObex owns seven U.S. patent applica
'/>"/>

SOURCE DiObex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
2. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
3. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
6. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
7. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
8. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
9. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
10. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
11. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., PLEASANTON,Calif.,Nov.24/PRNewswire-FirstCall...indevice-basedmechanicalcirculatorysupporttherapie...atitwillbeparticipatinginthe21stAnnualPiperJaffray...idV.Smith,executivevicepresidentandchieffinancialo...8:30a.m.,EasternStandardTime(5:30a.m.,PacificStand...
(Date:11/24/2009)..., SALTLAKECITY,Nov.24/PRNewswire/-- InfiniteMin...aunchofanewonlinevisiontherapyprogrameyeQ,thesoftw...ficetherapymethods. ,, eyeQ wasintroducedatthe...ypresidentelect,Dr.BradHabermehlbelievesthe eyeQ p...rningCenterinFlintMichigan.Itallowshispatientstoem...
(Date:11/24/2009)..., FRANKLIN,Mass.,Nov.24/PRNewswire-FirstCall/--...anydevelopingitsneedle-freeSymphony(TM)tCGMSystema...semonitoring(tCGM)systemanditsPrelude(TM)SkinPrepS...PatrickT.Mooney,M.D.,ChairmanandChiefExecutiveOffi...harmaceuticalsConference,sponsoredbytheNewYorkSoci...
Breaking Medicine Technology:Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2iMedX Announces Acquisition of Medware Inc 51017 1iMedX Announces Acquisition of Medware Inc 51017 2Endocare and Galil Medical Announce Settlement of Litigation 12928 1Endocare and Galil Medical Announce Settlement of Litigation 12928 2Wrong dose of heart meds too frequent in children 51010 1Wrong dose of heart meds too frequent in children 51010 2
... Dr. Fouad,Bachour, MD, FACC, director of interven...r, presented results of a study at the American He....sessionsdailynews.com/tuesday.pdf ) meeting in Or...s possible before a heart attack,patient arrives i...ay hours,and after hours. Door-to-balloon time is ...
... Figlin Highlights Phase 2 Data Showing 31%,Partia... Rate to Perifosine, Used as a Single Agent and P... Toxicity When Combined with Sorafenib, ...oday announced positive phase 1 & 2 data of perifo...ll carcinoma (RCC). In an oral presentation,entitl...
Other Medicine Technology:Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients 2Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 2Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 3Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 4Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 5Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 6Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 7
(Date:11/25/2009)...ELES,Nov.25/PRNewswire/--HairFairies,the headlice...willringintheholidayseasonwithaThanksgivingNitZapp...lineat1-877-285-0069willreceivetheirchoiceofafree,...noil.Inaddition,HairFairieswilloffer50%offitswhole...reseasonaldiscountsareavailableonline. ,, Theho...
(Date:11/25/2009)...,Calif.,Nov.25()/PRNewswire-FirstCall/--ErnestB.Re...oration(PinkSheets:ADHC),announcedtodaythatitsneww...rm,enablinginvestorstoeasilyaccesstimelyinformatio...beaccessedat: http://www.americandiversifiedholdin...andournewwebsiteallowsustoproviderelevantinformati...
(Date:11/25/2009)...rs from across the globe have come together to for...eir aim is to mobilise health professionals across...imate change. , The Council will be officially l...with a series of papers being published by the La... reduce greenhouse gas emissions, ahead of the UN ...
(Date:11/25/2009)...uth American medicinal herb proves effective in an...hDay News) -- An herb called Brazilian mint treats...ish researchers report. , Traditional healers i...to treat a range of health problems, including hea... the first to scientifically prove the pain-reliev...
(Date:11/25/2009)...mily members can panic, underestimate effects of ...lthDay News) -- Thanksgiving is a time of eating t...ng your elderly loved one to the emergency room. ,... why: When family members who have not seen each o...hey are often alarmed by the health of their older...
Breaking Medicine News(10 mins):Health News:Hair Fairies Kicks Off the Holiday Season With an All Natural Head Lice Product Giveaway 2Health News:Hair Fairies Kicks Off the Holiday Season With an All Natural Head Lice Product Giveaway 3Health News:American Diversified Holdings Corporation Announces New Website 2Health News:Senior doctors launch global movement to tackle climate change 2Health News:ER Visits for Elderly Rise During Thanksgiving 2Health News:ER Visits for Elderly Rise During Thanksgiving 3
...th care,information technology will be speaking on...d patient safety, HIT applications, privacy and,le...rmatics Symposium to be,held September 8-10, 2008,..., Massachusetts eHealth Collaborative; Mark,Levine...
...y and Two Rivers among Thomson Reuters 100 To...ILWAUKEE, Aug. 13 Three Aurora Health Care facili...omson Reuter as having,demonstrated the fastest, m...in the Thomson Reuters 100 Top Hospitals(R):,Perfo...
...ding developer,and provider of instrumentation and...s recently partnered with Italy-based NARDA Safety...d range of EMC components,including field probes, ...e and defense markets., With locations worldwide,...
...n to significantly involve their workers in long-t... This finding is among the results of a survey rel... New York (PRWEB) August 13, 2008 -- Empl...urvey released today by Buck Consultants, an ACS c...
...e Internet Modeling and Simulation Network, is bro...eractive research and training tools, systems and ...ol Hill. Complete coverage of the event can be fou...ssociation,s Internet Television Network, SimTV.or...
...ark, but numbers aren,t as high as some might susp...thDay News) -- The risk of relapse can linger for ... five years of what doctors call systemic therapy,...like to think these numbers are smaller than women...
Other Medicine News:Health News:Three Aurora Hospitals Named Top Performers in National Thomson Reuters Annual Survey 2Health News:Three Aurora Hospitals Named Top Performers in National Thomson Reuters Annual Survey 3Health News:Teseq USA and NARDA Safety Test Solutions to Offer Expanded Range of EMC Components to North American Customers 2Health News:Employee Involvement Is Key to Long-Term Pharmacy Cost Control, Finds Buck Consultants Survey 2Health News:Employee Involvement Is Key to Long-Term Pharmacy Cost Control, Finds Buck Consultants Survey 3Health News:Employee Involvement Is Key to Long-Term Pharmacy Cost Control, Finds Buck Consultants Survey 4Health News:NTSA's SimTV.org Broadcasts Video from Modeling & Simulation Event on Capitol Hill 2Health News:NTSA's SimTV.org Broadcasts Video from Modeling & Simulation Event on Capitol Hill 3Health News:Risk of Breast Cancer Relapse Can Linger 2Health News:Risk of Breast Cancer Relapse Can Linger 3
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: